The genetic basis for cardiac remodeling

Annual Review of Genomics and Human Genetics

Volumn 6, Issue , 2005, Pages 185-216

  Ahmad, Ferhaan ^a,b   Seidman, J G ^b   Seidman, Christine E ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Arrhythmogenic right ventricular dysplasia cardiomyopathy; Dilated cardiomyopathy; Hypertrophic cardiomyopathy; PRKAG2 cardiomyopathy; Restrictive cardiomyopathy

Indexed keywords

ACTIN; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN; CALCIUM; CALSEQUESTRIN; CONNECTIN; CYTOSKELETON PROTEIN; DILTIAZEM; GLYCOGEN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAMIN; LOSARTAN; MEMBRANE PROTEIN; MYOCYTE ENHANCER FACTOR 2; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; PROTEIN; RYANODINE RECEPTOR; SERUM RESPONSE FACTOR; SIMVASTATIN; TRANSCRIPTION FACTOR GATA 4; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T; UNINDEXED DRUG;

ALLELE; APOPTOSIS; CALCIUM HOMEOSTASIS; CONGESTIVE CARDIOMYOPATHY; DESMOSOME; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FABRY DISEASE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HEART; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SARCOPLASMIC RETICULUM;

ACTOMYOSIN; ANIMALS; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CARDIOMYOPATHY, RESTRICTIVE; FEMALE; GLYCOGEN STORAGE DISEASE; HUMANS; MALE; MODELS, CARDIOVASCULAR; MUTATION;

EID: 25844475225     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.6.080604.162132     Document Type: Review

References (189)

1. Ahmad F, Li D, Karibe A, Gonzalez O, Tapscott T, et al. 1998. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 98:2791-95
2. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, et al. 2002. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109:357-62
3. Arad M, Maron BJ, Gorham JM, Johnson WH, Saul JP, et al. 2005. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 352:362-72
4. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, et al. 2003. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107:2850-56
5. Badorff C, Knowlton KU. 2004. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med. Microbiol. Immunol. (Berlin) 193:121-26
6. Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, et al. 2004. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am. J. Med. Genet. 126A:349-54
7. Basso C, Corrado D, Thiene G. 1999. Cardiovascular causes of sudden death in young individuals including athletes. Cardial. Rev. 7:127-35
8. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. 1996. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? [see comments]. Circulation 94:983-91
9. Bauce B, Nava A, Rampazzo A, Daliento L, Muriago M, et al. 2000. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome Iq42-43. Am. J. Cardiol. 85:573-79
10. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, et al. 2002. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J. Am. Coll. Cardiol. 40:341-49
11. Bienengraeber M, Olson TM, Selivanov VA, Kathmann EC, O'Cochlain F, et al. 2004. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36:382-87
12. Bijvoet AG, Van Hirtum H, Vermey M, Van Leenen D, Van Der Ploeg AT, et al. 1999. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J. Pathol. 189:416-24
13. Bing W, Knott A, Redwood C, Esposito G, Purcell I, et al. 2000. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha-tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J. Mol. Cell. Cardiol. 32:1489-98
14. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, et al. 2001. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10:1215-20
15. Blair E, Redwood C, de Jesus Oliveira M, Moolman-Smook JC, Brink P, et al. 2002. Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ. Res. 90:263-69
16. Blanchard E, Seidman C, Seidman JG, LeWinter M, Maughan D. 1999. Altered crossbridge kinetics in the alphaMHC-403/+ mouse model of familial hypertrophic cardiomyopathy. Circ. Res. 84:475-83
17. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, et al. 1999. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 21:285-88
18. Bowles KR, Gajarski R, Porter P, Goytia V, Bachinski L, et al. 1996. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. J. Clin. Invest. 98:1355-60
19. Bozkurt B, Mann DL. 2000. Dilated cardiomyopathy. In Cardiovascular Medicine, ed. Willerson JT, JN Cohn, pp. 1034-53. New York: Churchill Livingstone
20. Brega A, Narula J, Arbustini E. 2001. Functional, structural, and genetic mitochondrial abnormalities in myocardial diseases. J. Nucl. Cardiol. 8:89-97
21. Brink PA, Ferreira A, Moolman JC, Weymar HW, van der Merwe PL, Corfield VA. 1995. Gene for progressive familial heart block type I maps to chromosome 19q13. Circulation 91:1633-40
22. Brugada R, Kelsey W, Lechin M, Zhao G, Yu QT, et al. 1997. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J. Invest. Med. 45:542-51
23. Chandra M, Rundell VL, Tardiff JC, Leinwand LA, De Tombe PP, Solaro RJ. 2001. Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am. J. Physiol. Heart Circ. Physiol. 280:H705-H13
24. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. 2004. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24:8467-76
25. Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EW, Houlston RS, et al. 1998. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 97:2049-58
26. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, et al. 1999. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98:465-74
27. Coronado R, Morrissette J, Sukhareva M, Vaughan DM. 1994. Structure and function of ryanodine receptors. Am. J. Physiol. 266:C1485-C504
28. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, et al. 1997. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J. Am. Coll. Cardiol. 30:1512-20
29. D'Adamo P, Fassone L, Gedeon A, Janssen EA, Bione S, et al. 1997. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am. J. Hum. Genet. 61:862-67
30. Daehmlow S, Erdmann J, Knueppel T, Gille C, Froemmel C, et al. 2002. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298:116-20
31. Dec GW, Fuster V. 1994. Idiopathic dilated cardiomyopathy. N. Engl J. Med. 331:1564-75
32. Deinum J, van Gool JM, Kofflard MJ, ten Gate FJ, Danser AH. 2001. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 38:1278-81
33. Deng Y, Schmidtmann A, Redlich A, Westerdorf B, Jaquet K, Thieleczek R. 2001. Effects of phosphorylation and mutation R145G on human cardiac troponin I function. Biochemistry 40:14593-602
34. Dimitrow PP, Czarnecka D, Kawecka-Jaszcz K, Dubiel JS. 2003. The influence of age on gender-specific differences in the left ventricular cavity size and contractility in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 88:11-16; discussion 6-7
35. Dimitrow PP, Czarnecka D, Kawecka-Jaszcz K, Dubiel JS. 2004. Sex-based comparison of survival in referred patients with hypertrophic cardiomyopathy. Am. J. Med. 117:65-66
36. Dworzak F, Casazza F, Mora M, De Maria R, Gronda E, et al. 1994. Lysosomal glycogen storage with normal acid maltase: a familial study with successful heart transplant. Neuromuscul. Disord. 4:243-47
37. Elliott K, Watkins H, Redwood CS. 2000. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 275:22069-74
38. Erdmann J, Hassfeld S, Kallisch H, Fleck E, Regitz-Zagrose V. 2000. Genetic variants in the promoter (g983G > T) and coding region (A92T) of the human cardiotrophin-1 gene (CTF1) in patients with dilated cardiomyopathy. Hum. Mutat. 16:448
39. Fananapazir L, Epstein ND. 1994. Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 89:22-32
40. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, et al. 1999. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 341:1715-24
41. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, et al. 2000. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106:1351-59
42. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, et al. 2000. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342:1077-84
43. Furlanello F, Bertoldi A, Dallago M, Furlanello C, Fernando F, et al. 1998. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin. Electrophysiol. 21:331-35
44. Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ, et al. 1996. A mouse model of familial hypertrophic cardiomyopathy. Science 272:731-34
45. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, et al. 1990. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62:999-1006
46. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitas K, et al. 2002. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30:201-4
47. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, et al. 2004. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36:1162-64
48. Goldfarb LG, Park KY, Cervenakova L, Gorokhova S, Lee HS, et al. 1998. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat. Genet. 19:402-3
49. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, et al. 2001. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 344:1823-31
50. Green KJ, Gaudry CA. 2000. Are desmosomes more than tethers for intermediate filaments? Nat. Rev. Mol. Cell Biol. 1:208-16
51. Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA. 1998. Frequency and phenotypes of familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 31:186-94
52. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, et al. 2003. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111:869-76
53. Hakimelahi S, Parker HR, Gilchrist AJ, Barry M, Li Z, et al. 2000. Plakoglobin regulates the expression of the anti-apoptotic protein BCL-2. J. Biol. Chem. 275:10905-11
54. Hamilton SR, Stapleton D, O'Donnell JB Jr, Kung JT, Dalal R, et al. 2001. An activating mutation in the gammal subunit of the AMP-activated protein kinase. FEBS Lett. 500:163-68
55. Harada K, Potter JD. 2004. Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J. Biol. Chem. 279:14488-95
56. Harada K, Takahashi-Yanaga F, Minakami R, Morimoto S, Ohtsuki I. 2000. Functional consequences of the deletion mutation deltaGluloO in human cardiac troponin T. J. Biochem. (Tokyo) 127:263-68
57. Heller MJ, Nili M, Homsher E, Tobacman LS. 2003. Cardiomyopathic tropomyosin mutations that increase thin filament Ca2+ sensitivity and tropomyosin N-domain flexibility. J. Biol. Chem. 278:41742-48
58. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. 2000. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation 102:1950-55
59. Hodgson DM, Zingman LV, Kane GC, Perez-Terzic C, Bienengraeber M, et al. 2003. Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J. 22:1732-42
60. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. 2001. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17:524
61. Ikemoto N, Yamamoto T. 2000. Postulated role of inter-domain interaction within the ryanodine receptor in Ca(2+) channel regulation. Trends Cardiovasc. Med. 10:310-16
62. Isaacs H Jr. 2004. Fetal and neonatal cardiac tumors. Pediatr. Cardiol. 25:252-73
63. Jha S, Kao A, Desai S, St. John Sutton MG, Jessup M, Keating MT. 2001. Identification of a new locus for autosomal dominant dilated cardiomyopathy on chromosome 9q22-q31. Circulation 104:11-135
64. Jung M, Poepping I, Perrot A, Ellmer AE, Wienker TF, et al. 1999. Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22. Am. J. Hum. Genet. 65:1068-77
65. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, et al. 2000. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343:1688-96
66. Kamphoven JH, Stubenitsky R, Reuser AJ, Van Der Ploeg AT, Verdouw PD, Duncker DJ. 2001. Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice. Physiol. Genomics 5:l71-79
67. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, et al. 1994. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nature (Genetics) 7:546-51
68. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. 1999. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24:22-25
69. Kimura A, Harada H, Park JE, Nishi H, Satoh M, et al. 1997. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 16:379-82
70. Knoll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I, et al. 2002. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111:943-55
71. Kobayashi T, Dong WJ, Burkart EM, Cheung HC, Solaro RJ. 2004. Effects of protein kinase C dependent phosphorylation and a familial hypertrophic cardiomyopathy-related mutation of cardiac troponin I on structural transition of troponin C and myofilament activation. Biochemistry 43:5996-6004
72. Kohler J, Chen Y, Brenner B, Gordon AM, Kraft T, et al. 2003. Familial hypertrophic cardiomyopathy mutations in troponin I (K183D, G203S, K206Q) enhance filament sliding. Physiol. Genomics 14:117-28
73. Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM, et al. 1995. Linkage of familial dilated cardiomyopathy to chromosome 9. Am. J. Hum. Genet. 57:846-52
74. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, et al. 2001. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 103:485-90
75. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, et al. 2004. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J. Clin. Invest. 113:370-78
76. Lang R, Gomes AV, Zhao J, Housmans PR, Miller T, Potter JD. 2002. Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy. J. Biol. Chem. 277:11670-78
77. Le Corvoisier P, Park HY, Carlson KM, Donahue MP, Marchuk DA, Rockman HA. 2003. Impact of genetic polymorphisms on heart failure prognosis. Arch. Mal. Coeur. Vaiss. 96:197-206
78. Lechin M, Yu QT, Roberts R, Quinones MA, Marian AJ. 1995. Angiotensin I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 92:1808-12
79. Leung CL, Green KJ, Liem RK. 2002. Plakins: a family of versatile cytolinker proteins. Trends Cell Biol. 12:37-45
80. Li D, Ahmad F, Gardner MJ, Weilbaecher D, Hill R, et al. 2000. The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14. Am. J. Hum. Genet. 66:148-56
81. Li Y, Corradetti MN, Inoki K, Guan KL. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29:32-38
82. Liew CC, Dzau VJ. 2004. Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 5:811-25
83. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, et al. 2001. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789-91
84. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, et al. 2002. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106:3068-72
85. Lu QW, Morimoto S, Harada K, Du CK, Takahashi-Yanaga F, et al. 2003. Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+ desensitization. J. Mol. Cell. Cardiol. 35:1421-27
86. MacLennan DH, Kranias EG. 2003. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell. Biol. 4:566-77
87. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. 1993. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342:1085-86
88. Mariot P, Prevarskaya N, Roudbaraki MM, Le Bourhis X, Van Coppenolle F, et al. 2000. Evidence of functional ryanodine receptor involved in apoptosis of prostate cancer (LNCaP) cells. Prostate 43:205-14
89. Maron BJ. 2002. Hypertrophic cardiocmyopathy: a systematic review. JAMA 287:1308-20
90. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, et al. 2003. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 41:974-80
91. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, et al. 2000. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102:858-64
92. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, et al. 2000. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-76
93. Matsuishi T, Yoshino M, Terasawa K, Nonaka I. 1984. Childhood acid maltase deficiency. A clinical, biochemical, and morphologic study of three patients. Arch. Neurol. 41:47-52
94. McKinsey TA, Olson EN. 2004. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20:206-13
95. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, et al. 2000. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355:2119-24
96. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. 1999. Prevalence of lysosomal storage disorders. JAMA 281:249-54
97. Melberg A, Oldfors A, Blomstrom-Lundqvist C, Stalberg E, Carlsson B, et al. 1999. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann. Neurol. 46:684-92
98. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. 1997. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am. J. Hum. Genet. 61:909-17
99. Michele DE, Albayya FP, Metzger JM. 1999. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes. Nat. Med. 5:1413-17
100. Milan D, Jeon JT, Looft C, Amarger V, Robic A, et al. 2000. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288:1248-51
101. Miller LW, Missov ED. 2001. Epidemiology of heart failure. Cardiol. Clin. 19:547-55
102. Miller T, Szczesna D, Housmans PR, Zhao J, de Freitas F, et al. 2001. Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponinT (I79N) mutation. J. Biol. Chem. 276:3743-55
103. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, et al. 1999. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313-22
104. Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, et al. 1999. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J. Clin. Invest. 103:R39-43
105. Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, et al. 2003. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111:209-16
106. Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, et al. 2002. Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 99:913-18
107. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, et al. 2000. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 9:1453-59
108. Muchir A, Medioni J, Laluc M, Massart C, Arimura T, et al. 2004. Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. Muscle Nerve 30:444-50
109. Munclinger MJ, Patel JJ, Mitha AS. 2000. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. S. Afr. Med. J. 90:61-68
110. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, et al. 2001. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104:128-30
111. Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, et al. 2003. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 108:395-98
112. Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, et al. 2000. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J. Am. Coll. Cardiol. 36:2226-33
113. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, et al. 1998. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 338:1248-57
114. Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, et al. 2002. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105:446-51
115. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, et al. 2004. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J. Clin. Invest. 113:357-69
116. Norgett EE, Hatsell SJ, Carvajal-Huerta L, Cabezas JC, Common J, et al. 2000. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum. Mol. Genet. 9:2761-66
117. Olson EN, Schneider MD. 2003. Sizing up the heart: development redux in disease. Genes Dev. 17:1937-56
118. Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. 2000. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 32:1687-94
119. Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating MT, Jockusch BM. 2002. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 105:431-37
120. Olson TM, Keating MT. 1996. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J. Clin. Invest. 97:528-32
121. Olson TM, Kishimoto NY, Whitby FG, Michels W. 2001. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J. Mol. Cell Cardiol. 33:723-32
122. Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. 1998. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280:750-52
123. Olsson MC, Palmer BM, Leinwand LA, Moore RL. 2001. Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy. Am. J. Physiol. Circ. Physiol. 280:H1136-44
124. Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. 1997. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation 95:2434-40
125. Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, et al. 2002. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 87:270-75
126. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, et al. 1998. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 32:825-30
127. Palmer BM, Fishbaugher DE, Schmitt JP, Wang Y, Alpert NR, et al. 2004. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 287:H91-H99
128. Patel R, Lim DS, Reddy D, Nagueh SF, Lutucuta S, et al. 2000. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 32:2369-77
129. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, et al. 2001. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104:317-24
130. Peters S, Peters H, Thierfelder L. 1999. Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy. Int. J. Cardiol. 71:243-50
131. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, et al. 1996. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 13:63-69
132. Deleted in proof
133. Prestle J, Janssen PM, Janssen AP, Zeitz O, Lehnart SE, et al. 2001. Overexpression of FK506-binding protein FKBP 12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca(2+) leak from the sarcoplasmic reticulum and increases contractility. Circ. Res. 88:188-94
134. Priori SG, Corr PB. 1990. Mechanisms underlying early and delayed after depolarizations induced by catecholamines. Am. J. Physiol. 258:H1796-H805
135. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, et al. 2001. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196-200
136. Raben N, Jatkar T, Lee A, Lu N, Dwivedi S, et al. 2002. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol. Ther. 6:601-8
137. Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, et al. 1994. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum. Mol. Genet. 3:959-62
138. Rampazzo A, Nava A, Erne P, Eberhard M, Vian E, et al. 1995. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Hum. Mol. Genet. 4:2151-54
139. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, et al. 2002. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am. J. Hum. Genet. 71:1200-6
140. Rampazzo A, Nava A, Miorin M, Fonderico P, Pope B, et al. 1997. ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics 45:259-63
141. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND. 1995. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 92:3864-68
142. Redwood C, Lohmann K, Bing W, Esposito GM, Elliott K, et al. 2000. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ. Res. 86:1146-52
143. Redwood CS, Moolman-Smook JC, Watkins H. 1999. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc. Res. 44:20-36
144. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, et al. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227-32
145. Richard P, Isnard R, Carrier L, Dubourg O, Donatien Y, et al. 1999. Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J. Med. Genet. 36:542-45
146. Roberts R, Sigwart U. 2001. New concepts in hypertrophic cardiomyopathies, part I. Circulation 104:2113-16
147. Roberts R, Sigwart U. 2001. New concepts in hypertrophic cardiomyopathies, part II. Circulation 104:2249-52
148. Robinson P, Mirza M, Knott A, Abdulrazzak H, Willott R, et al. 2002. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 277:40710-16
149. Roopnarine O. 2003. Mechanical defects of muscle fibers with myosin light chain mutants that cause cardiomyopathy. Biophys. J. 84:2440-49
150. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, et al. 2004. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci. USA 101:10132-36
151. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. 1999. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Biophys. Res. Commun. 262:411-17
152. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, et al. 2003. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299:1410-13
153. Schonberger J, Levy H, Grunig E, Sangwatanaroj S, Fatkin D, et al. 2000. Dilated cardiomyopathy and sensorineural hearing loss: a heritable syndrome that maps to 6q23-24. Circulation 101:1812-18
154. Seidman CE, Seidman JG. 2001. Hypertrophic cardiomyopathy. In The Metabolic and Molecular Basis of Inherited Disease, ed. CR Scriver, AL Beaudet, NS Sly, D Valle, B Childs, K Kinzler, B Vogelstein, pp. 5433-50. New York: McGraw-Hill
155. Seidman JG, Seidman C. 2001. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104:557-67
156. Seidman JG, Seidman C, DePalma SR. Cardiogenomics Database. http://cardio genomics.med.harvard.edu//project-det ail?project_id=230#data
157. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, et al. 2002. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109:1013-20
158. Semsarian C, Healey MJ, Fatkin D, Giewat M, Duffy C, et al. 2001. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33:2055-60
159. Severini GM, Krajinovic M, Pinamonti B, Sinagra G, Fioretti P, et al. 1996. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 31:193-200
160. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, et al. 2000. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat. Genet. 24:153-56
161. Shen WK, Edwards WD, Hammill SC, Gersh BJ. 1994. Right ventricular dysplasia: a need for precise pathological definition for interpretation of
162. Siu BL, Niimura H, Osborne JA, Fatkin D, MacRae C, et al. 1999. Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circulation 99:1022-26
163. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, et al. 1998. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J. Clin. Invest. 101:1775-83
164. Stewart S, MacIntyre K, Capewell S, McMurray JJ. 2003. Heart failure and the aging population: an increasing burden in the 21st century? Heart 89:49-53
165. Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, et al. 1999. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J. Am. Coll. Cardiol. 34:2035-42
166. Sylvius N, Tesson F, Gayet C, Charron P, Benaiche A, et al. 2001. A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16. Am. J. Hum. Genet. 68:241-46
167. Szczesna D, Ghosh D, Li Q, Gomes AV, Guzman G, et al. 2001. Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation. J. Biol. Chem. 276:7086-92
168. Szczesna D, Zhang R, Zhao J, Jones M, Guzman G, Potter JD. 2000. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J. Biol. Chem. 275:624-30
169. Tabib A, Miras A, Taniere P, Loire R. 1999. Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases. Eur. Heart J. 20:900-3
170. Takahashi-Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, et al. 2001. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33:2095-107
171. Tesson F, Dufour C, Moolman JC, Carrier L, al-Mahdawi S, et al. 1997. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J. Mol. Cell. Cardiol. 29:831-38
172. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, et al. 1994. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77:701-12
173. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, et al. 2001. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10:189-94
174. Towbin IA, Hejtmancik IF, Brink P, Gelb B, Zhu XM, et al. 1993. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87:1854-65
175. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus I, et al. 2000. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106:655-62
176. Tyska MJ, Hayes E, Giewat M, Seidman CE, Seidman IG, Warshaw DM. 2000. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophice cardiomyopathy. Circ. Res. 86:737-44
177. Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, et al. 2003. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42:2014-27
178. Venkatraman G, Harada K, Gomes AV, Kerrick WG, Potter JD. 2003. Different functional properties of troponin T mutants that cause dilated cardiomyopathy. J. Biol. Chem. 278:41670-76
179. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, et al. 1995. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11:434-37
180. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, et al. 1995. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332:1058-64
181. Watkins H, Rosenzweig A, Hwang D, Levi T, McKenna W, et al. 1992. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326:1108-14
182. Westfall MV, Borton AR, Albayya FP, Metzger IM. 2002. Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ. Res. 91:525-31
183. Xing Y, Musi N, Fujii N, Zou L, Luptak I, et al. 2003. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 278:28372-77
184. Xiong D, Lee GH, Badorff C, Dorner A, Lee S, et al. 2002. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat. Med. 8:872-77
185. Yamamoto S, Tsyplenkova VG, James TN. 2000. Morphological patterns of death by myocytes in arrhythmogenic right ventricular dysplasia. Am. J. Med. Sci. 320:310-19
186. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, et al. 2000. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102:3046-52
187. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. 2002. Class II histone deacetylases act as signal-responsive repressers of cardiac hypertrophy. Cell 110:479-88
188. Zhang J, Kumar A, Stalker HJ, Virdi G, Ferrans VI, et al. 2001. Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy. Clin. Genet. 59:248-56
189. Zingman LV, Hodgson DM, Bast PH, Kane GC, Perez-Terzic C, et al. 2002. Kir6.2 is required for adaptation to stress. Proc. Natl. Acad. Sci. USA 99:13278-83